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ABSTRACT
The most important subgroup ol breast cancer patients for which
reliable prognostic factors are needed are women without axillary lymph
node involvement. Although overall, these patients have a good prognosis,
it is known that 20-30% will experience a recurrence of the disease. To
determine the prognostic significance of P53 tumor suppressor gene mu
tation, specimens from 113 primary breast cancers were evaluated for the
presence of /'5.Ã•alterations, as detected by cDNA sequencing of the entire
coding sequence of the gene. The median follow-up for patients was 105
months. P53 gene mutation was an independent prognostic marker of
early relapse and death. Our results suggest that P53 gene mutations could
be an important factor to identify node-negative patients who have a poor
prognosis in the absence of adjuvant therapy. Prospective studies should
be designed to determine which therapy should be performed in this
subgroup of patients.
INTRODUCTION
Tumor involvement of the axillary lymph nodes has been the
primary parameter in making decisions on adjuvant therapy for breast
cancer patients because it is known that these patients have both a
high risk for recurrence and a shorter overall survival time. However,
20-30% of lymph node-negative breast cancer patients will relapse
with a local recurrence or distant metastasis ( 1). Reliable prognostic
markers are needed to help clinicians identify this subset of patients
and arrive at more rational treatment decisions. The importance of
identifying high-risk patients at diagnosis is supported by the evidence
of an improved survival after chemotherapy for specific subsets of
patients with lymph node-negative breast cancer (2, 3). A variety of
molecular genetic changes have been described in breast cancer.
Oncogene and tumor suppressor gene alterations have been studied in
an attempt to define the molecular correlation of prognosis and the
clinical behavior of breast cancer phenotype (4). Among those, the
P53 tumor suppressor gene has become the focus of intensive studies.
The current and most powerful model of wild-type p53 function is one
in which p53 monitors the genome for DNA damage (5). After
treatment of cells with DNA damaging agents, p53 protein levels are
increased by posttranslational stabilization and can transactivate var
ious genes that may be related to cell cycle arrest or apoptosis (6).
Arrest of cell cycle progression following DNA damage is thought to
represent a basic protective mechanism preventing replication of
damaged template DNA. If damage is irreparable, the cell may be
driven to the apoptotic pathway, thus preventing replication of defec
tive cells. Mutations in the P53 tumor suppressor gene are the most
frequent known genetic alterations in all human cancers (7). Most of
the biologically significant mutations impair the ability of p53 to
participate to the maintenance of genomic stability. Consequently.
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tumors lacking normal p53 might be expected to be prone to delete
rious mutations and to be more aggressive clinically. Many studies
have examined the association between breast cancer prognosis and
p53 protein expression in tumor cells (8-16). The use of IHC2 was
based on the fact that missense mutations normally result in an
increased half-life of the protein product and a consequent accumu
lation of the mutant p53 protein in the nucleus. Differences in meth
odologies and variability in the frequency and intensity of immuno-
reactivity with p53-specific antibodies may explain discrepant results
reported for the prognostic significance of p53 accumulation within
the same tumor type (8, 11-15). In contrast, there have been only a
few reports on P53 gene alterations in large series of breast cancers.
Nevertheless, recent studies reported the prognostic value of P53
mutations in nonselected breast cancers comprising both node-nega
tive and node-positive tumors (17. 18). In our study, the complete
coding region of the P53 gene was sequenced from 113 node-negative
breast cancers. In parallel, immunohistochemical studies were per
formed using two monoclonal antibodies directed against p53. The
P53 status was then related to prognosis for relapse-free survival and
overall survival, with a median duration of follow-up of 105 months.
MATERIALS AND METHODS
Patient Population. Entered in this study were randomly selected tumor
samples from 113 breast cancer patients treated and followed up at the Center
LÃ©onBÃ©rard.All patients had a primary breast tumor and hislopathologically
verified carcinoma-free axillary lymph nodes. The median age of patients at
the time of diagnosis was 59 years (range. 32-87 years). Patients had been
surgically treated by mastectomy or lumpectomy and axillary dissection.
Postoperative radiotherapy was given to 47 patients. Adjuvant chemotherapy
consisting primarily of three courses of i.v. 5-fluorouracil. Adriamycin. and
methotrexate was offered to all patients with a tumor >30 mm (n = 27
patients). Adjuvant hormonal therapy (tamoxifen) was given to postmeno-
pausal patients having positive estrogen receptor tumors (n = 57).
The mean follow-up was 103 Â±34 months for patients still alive (median
follow-up. 105 months). All patients treated for breast cancer were seen on a
regular basis every 6 months for 5 years: after 5 years, they were seen on a
yearly basis. The follow-up evaluation consisted of a clinical evaluation,
physical examination. X-ray procedures, and serum chemistry tests.
Tumor samples were collected at the Department of Pathology of the Center
LÃ©onBÃ©rard.Tumors were pure histological variants of invasive breast carci
nomas comprising 98 ductal. 10 lobular. 2 mucinous. I tubular. 1 cribriform,
and 1 squamous cell metaplastic carcinomas. Tumor si/.e was recorded as the
maximum tumor diameter in a fresh mastectomy specimen. The median size of
collected tumors was 25 mm (range. 7-70 mm). Histopathological type and
grade of the carcinomas were reevaluated according to WHO criteria and
Scarff-Bloom-Richardson grading, respectively (19). Results of the cytosolic
estrogen and progesterone receptor assays (cutoff. 10 fmol/mg of protein),
which had been performed on snap-frozen tumor samples by the dextran-
coated charcoal method, were available from patient records in 112 cases. A
sample was carefully selected from the most viable part of the tumor to be snap
frozen in liquid nitrogen, transferred, and stored at â€”¿70Â°Cuntil analysis. A
slide was generated to estimate the percentage of tumor cells. All samples
studied contained 60% or more malignant cells.
: The abbreviations used are: 1HC. immunohistochemistry: RH. relative ha/ard.
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This retrospective study included 26% of tumors from node-negative pa
tients treated at the Center LÃ©onBÃ©rardbetween 1983 and 1989. The studied
population was representative of node-negative breast cancer patients treated at
the Center LÃ©onBÃ©rarduring this period (median age of patients at the time
of diagnosis. 57 years; median tumor size of invasive breast carcinomas, 22
mm; histopathological types: ductal carcinomas, 74%; lobular carcinomas, 8%;
others, 18%).
IHC of Paraffin-embedded Tissue. Intracellular p53 protein levels were
evaluated in 112 tumors by immunohistochemical analysis. Four-/xm sections
from Bouin-fixed. paraffin-embedded blocks were deparaffmized in toluene,
transferred to 100% and 95% ethanol, and air dried. They were then treated
with 5% hydrogen peroxide for 20 min to exhaust endogenous peroxidase.
Tissue sections were placed in sodium citrate solution (0.01 M. pH 6.0) and
then incubated three times for 5 min each in a 800-W microwave oven. After
preincubation in 1% BSA in PBS. sections were incubated for 90 min at 37Â°C
with mouse monoclonal p53 antibodies DO-7 (Dako Corp.) or PAblSOl
(Oncogene Science) diluted 1:50, washed, and reacted with streptavidin-biotin-
peroxidase reagents (Dako) and diaminobenzidine chromogen. Sections were
slightly counterstained with hematoxylin. The entire slides were microscopi
cally evaluated separately by two investigators. The localization and the
intensity of the staining and the percentage of positive-stained tumor cells were
estimated by each investigator. When the values determined by the two
investigators differed by greater than 5%, the score was decided by joint
examination. A threshold of 5% cells staining was chosen to score tumors as
IHC positive. In all series, a set of breast cancers with high levels of p53 was
used as the positive control. Negative controls were obtained by omission of
the primary antibody.
Sequence-based Analysis of P53. The method was essentially as described
by Sjogren et al. (20). RNA was prepared from the frozen tumors under
stringent conditions to avoid degradation and contamination. This was fol
lowed by an enzymatic conversion of the RNA to cDNA. P53 was amplified
from the tumor cDNA by the PCR using four overlapping primer pairs
covering the complete coding region of the P53 gene. Biotin-labeled PCR
products were generated with one of the primers (in each pair) being modified
with a biotin molecule, which facilitated solid-phase sequencing. Solid-phase
sequencing was carried out using AutoLoad solid phase sequencing combs and
T7 DNA polymerase (Pharmacia Biotech). The sequencing products generated
were analyzed using an automated laser fluorescence ALF DNA sequencer
(Pharmacia Biotech). The limit for hÃ©tÃ©rozygoted tection in wild-type back
ground was determined to be 25%.' All mutations were confirmed by ream-
plifying the relevant cDNAs and sequencing the new PCR products.
Statistical Methods. Probability of survival was estimated with the
Kaplan-Meier method. The equality between survival curves was tested with
the log rank test. The Cox proportional hazards model was used to estimate the
effect of P53 mutations on overall survival, with several prognostic factors
taken into account simultaneously. The analyses were carried out using the
JMP software for Macintosh (version 3.2) from the SAS institute (Cortex AB,
Solna, Sweden).
RESULTS
Detection and Characterization of P53 Mutations. A total of
113 breast cancer RNA samples were analyzed by cDNA sequencing.
Mutations were detected in tumors from 18 (16%) patients (Table 1).
All mutations were missense mutations. Thirteen of them were located
within evolutionarily conserved domains of P53. G:C to A:T transi
tions were predominant (12 of 18 mutations). This type of alterations
is thought to be involved in spontaneous mutations (7). Codons 110,
175, 248, 273, and 337 (CGN), which encode arginine, accounted for
10 of the 18 mutations.
Immunohistochemical Analysis of p53 Protein Accumulation.
112 tumors from the total were examined by IHC for p53 protein
overexpression using antibodies PAblSOl (p53IHC-PAbl801) and
DO-7 (p53IHC-DO7). The localization and the intensity of the stain
ing and the percentage of positive cells were assessed without knowl
edge of clinical outcome and P53 mutation status. p53 labeling was
restricted to tumor cell nuclei. Cytoplasmic staining, as reported by
other authors (21), was not observed in our series. In agreement with
previous reports (22, 23), we found a discrepancy between the im-
munoreactivity of the different p53 monoclonal antibodies. Thirty
tumors were positive using DO-7, although only 16 of them expressed
a mutant P53 gene. Using PAblSOl, overexpression of the p53
protein was found in 13 tumors. Ten of these contained mutant P53.
Thus, a significant fraction of IHC-positive tumors did not show any
gene alterations by sequencing. It is noticeable that some of these
tumors displayed up to 70% positive cells. Therefore, as previously
reported, the proportion of p53-stained cells is not an exact represen
tation of the number of cancer cells bearing a mutation within a tumor
(24).
P53 Mutations and Pathobiological Variables. Table 2 shows
the distribution of some tumors and patients characteristics by P53
status, x2 analysis revealed significant associations between the pres
ence of P53 mutations and high histological grade (P < 0.001), lack
of estrogen receptors (P = 0.0044), and lack of progesterone receptors
(P = 0.0392). No correlation was observed between P53 gene muta
tion and the age at diagnosis or tumor size.
Survival Analysis. Kaplan-Meier curves demonstrated signifi
cantly shorter overall (P = 0.0026) and relapse-free (P = 0.0077)
survival for patients who had a primary tumor with P53 alterations
(Figs. 1 and 2). Only 60% of patients with P53 mutations were alive
5 years after surgery, compared with 88% for those lacking detectable
mutation. Together with patient age, P53 status was the only factor
that predicted survival. In univariate analyses, tumor size (RH, 0.98;
P = 0.28). estrogen receptor (RH, 0.79; P = 0.42), progesterone
receptor (RH, 0.65; P = 0.13). and histological grade (RH, 0.92;
P = 0.78) had no significant power. The RH associated with a P53
mutation was 1.82 (95% confidence interval, 1.08-3.06; P = 0.02).
The detection of a gene mutation by cDNA sequencing had a sub
stantially greater prognostic value than the observation of a p53
Table 2 Distribution of Iunior and patient characteristics bv P53 ÃŸenestatus
' N. Tooke and E. LÃ¶fman,unpublished data.
Covariate (no. ofpatients)Estrogen
receptor (112), a 10 fmol/mg
Progeslerone receplor (112), alO fmol/mg
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Fig. 2. Relapse-free survival by P53 gene status.
protein accumulation by IHC. RHs associated with p53 accumulation
detected by DO-7 and PAb 1801 were 1.53 (P = 0.05) and 1.63
(P = 0.10), respectively. As previously mentioned, in line with other
investigators (25-27), we chose a threshold of 5% cells staining to
score tumors as IHC-positive. This subjective choice was based on the
decision not to take into consideration scattered single p53-positive
cells that could reflect microenvironmental stresses in individual cells
rather than a widespread change throughout the neoplastic cells. As
shown in Table 3, depending on the antibody, the variation of the
cutoff affected in a different way the prognostic significance of p53
protein accumulation. This confirms that p53 immunostaining de
pends greatly on the conditions and reagents used in the test and
illustrates the need for optimization of each individual antibody used
in immunohistochemical studies.
Next, we investigated whether P53 status maintained its prognostic
value for survival in the presence of information provided by other
variables. The variables used for the multivariate analysis were age at
diagnosis, tumor size, and estrogen and progesterone receptors. Infor
mation on 100 patients fulfilled the criteria set by the program. As
shown in Table 4, P53 mutation was an independent prognostic factor
for survival, with RHs of the same magnitude in both univariate and
multivariate models. When the same parameters (age at diagnosis,
tumor size, and estrogen and progesterone receptors) were considered,
the prognostic value of p53 protein accumulation was statistically
significant only for p53IHC-PAbl801 (cutoff. 1%; RH, 1.83;
P = 0.04). Tests using other thresholds of positivity and/or the DO-7
antibody had no prognostic significance in multiple regression
analysis.
DISCUSSION
To date, seven independent studies, using different methodologies,
evaluated the prognostic value of genetic alterations of the P53 tumor
suppressor gene in invasive breast cancers (17, 18, 23, 26, 28-30). All
but one (30) observed a strong association of P53 mutation with poor
survival. The median clinical follow-up of these studies varied from
Table 3 Cav picpeffforal lui-ani ttnivariatf analysis of p53 protein accumulatimi
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' CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor.
'Cutoff. 10 fmo!/mg of protein.
24 to 60 months. To our knowledge, our study is the first one
conducted on a large series of node-negative breast cancer patients
(n = 113) with a prolonged clinical follow-up (median duration of
follow-up, 105 months). A follow-up of patients over a long time
course is of great importance considering the relative good prognosis
of breast cancer in patients without axillary lymph nodes invasion.
Using a cDNA-based sequencing method, we searched for mutations
in the entire coding region of the P53 gene. The frequency of P53
missense mutations (16%) is in concordance with data reported by
others (17). Although missense mutations are the most frequent alter
ations in the P53 gene, nonsense mutations, deletions, and insertions
have been recently reported at an unusual frequency in breast cancers
(17, 18). The lack of detection of these types of mutation in our study
could be either linked to the low number of detected mutations or due
to a differential pattern of mutations among populations, as suggested
previously (27, 31). p53 protein accumulation was detected in a
number of tumors expressing wild-type P53. as assessed by cDNA
sequencing. False-negative sequencing results may occur as a conse
quence of contamination of tumor samples by adjacent normal tissue.
However, the manner in which the tumor material was isolated in this
study should have minimized such risk. Another explanation is the
presence of mutations in noncoding regions of the gene. Alternatively,
the accumulation of wild-type p53 may occur in response to a variety
of stresses including DNA damage or hypoxia. Following the latter
hypothesis, one could expect that the nuclear accumulation of wild-
type p53 in tumor cells would be a predictive factor of favorable
outcome. Further studies are necessary to test this hypothesis. How
ever, it is noticeable that all four patients with a negative sequence
tumor displaying >40% stained cells by IHC, using the DO-7 anti
body, did not relapse and were still alive by the end of the study (mean
follow-up of these patients, 104 months).
Our data clearly show that the detection of a P53 gene alteration
constitutes a factor of poor prognosis. By the end of our study period,
50% of patients with mutant P53 had died, in contrast to 23% of
patients with wild-type P53. More strikingly, among patients who did
not receive adjuvant systemic chemotherapy, 50% (5 of 10) of the
patients with mutant P53 died within 5 years after surgery, in contrast
to only 9% (7 of 75) of the patients with wild-type P53. This
observation indicates that among breast cancers usually classified as
tumors of good prognosis, P53 mutations identify a subpopulation of
aggressive tumors. Which therapy should be offered to these patients?
Two recent nonrandomized studies, one based on cDNA sequencing
and the other on IHC. provided indirect evidence of a beneficial effect
from radiotherapy in preventing local relapse among node-negative
patients with tumors displaying P53 abnormality (25, 32). In these
studies, most of the patients were treated either by surgery only or by
surgery and locoregional radiotherapy. Considering the possible im
pact on overall survival, the benefit from a systemic therapy (chem
otherapy and/or hormonotherapy) should also be evaluated. It is
known that antiestrogens and genotoxic drugs used in chemotherapy
modulate p53 activity (33, 34). However, in spite of numerous studies,
the relationship between the P53 status and the activity of anticancer
agents remains unclear. There are theoretical arguments for both
increased and decreased chemosensitivity in tumors with mutant P53
(35-37). In our study, based on the size of the tumor, 27 patients were
treated with chemotherapy at the time of diagnosis. Eight of these
patients had a tumor with mutant P53. Among them, six were still
alive 5 years after surgery. The overall survival was not significantly
different (P = 0.3547) from the patients with wild-type P53 who
received a similar treatment. In contrast, P53 mutation was a signif
icant prognostic factor for overall survival (P = 0.0065) among
patients who did not receive systemic chemotherapy. Obviously, no
conclusion can be drawn from these small subgroups of patients.
Considering the high prognostic power of P53 mutations, prospective
and randomized trials should be designed to evaluate the benefit of
node-negative patients with a mutant P5.i-expressing tumor from
specific adjuvant therapies.
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